We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
ORELABRUTINIB‐LENALIDOMIDE‐RITUXIMAB (OLR) IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM PHASE 2 POLARIS STUDY IN CHINA.
- Authors
Zhang, H.; Su, L.; Liu, L.; Bai, O.; Song, Z.; Zhao, Z.; He, C.; Guo, Q.; Wang, X.; Li, W.; Qiu, L.; Li, L.; Zhou, S.; Fei, Y.; Meng, B.
- Abstract
Peripheral blood MRD (PB-MRD) and bone marrow MRD (BM-MRD) were evaluated using qPCR (<10 SP -6 sp ). B Introduction: b In recent years, chemo-free regimens have become one of the hot spots for the exploration of first-line therapy for mantle cell lymphoma (MCL). Pts received OLR-induction therapy on a 28-day cycle for 6 cycles (O, 150 mg/d; L, 15 mg on days 1-21, then 20 mg of cycles 2-6 if tolerated or 10 mg if not tolerated; R, 375 mg/m SP 2 sp on days 1, 8, 15, 22, then day 1 of cycles 3, 5), followed by OLR-maintenance therapy for up to 18 cycles.
- Subjects
CHINA; MANTLE cell lymphoma; BRUTON tyrosine kinase; CIRCULATING tumor DNA
- Publication
Hematological Oncology, 2023, Vol 41, p752
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_600